Cytokinetics - CYTK Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $79.33
  • Forecasted Upside: 14.88%
  • Number of Analysts: 15
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 13 Buy Ratings
  • 0 Strong Buy Ratings
$69.06
▲ +1.06 (1.56%)

This chart shows the closing price for CYTK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cytokinetics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CYTK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CYTK

Analyst Price Target is $79.33
▲ +14.88% Upside Potential
This price target is based on 15 analysts offering 12 month price targets for Cytokinetics in the last 3 months. The average price target is $79.33, with a high forecast of $108.00 and a low forecast of $50.00. The average price target represents a 14.88% upside from the last price of $69.06.

This chart shows the closing price for CYTK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 15 investment analysts is to moderate buy stock in Cytokinetics. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 13 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/23/2022
  • 0 strong buy ratings
  • 13 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/21/2023
  • 0 strong buy ratings
  • 13 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/21/2023
  • 0 strong buy ratings
  • 13 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/20/2023
  • 0 strong buy ratings
  • 13 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/18/2023
  • 0 strong buy ratings
  • 13 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/16/2024
  • 0 strong buy ratings
  • 13 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/16/2024
  • 0 strong buy ratings
  • 13 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/15/2024

Latest Recommendations

  • 0 strong buy ratings
  • 13 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/9/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$108.00Low
4/8/2024Truist FinancialReiterated RatingBuy ➝ Buy$86.00Low
3/6/2024MizuhoLower TargetBuy ➝ Buy$103.00 ➝ $99.00Low
3/4/2024OppenheimerReiterated RatingOutperform ➝ Outperform$107.00Low
2/28/2024HC WainwrightReiterated RatingBuy ➝ Buy$94.00Low
2/28/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$108.00Low
1/24/2024UBS GroupDowngradeBuy ➝ Neutral$61.00 ➝ $92.00Low
1/22/2024MizuhoBoost TargetBuy ➝ Buy$80.00 ➝ $103.00Low
1/5/2024Morgan StanleyReiterated RatingOverweight ➝ Equal Weight$60.00 ➝ $90.00Low
12/28/2023Truist FinancialBoost TargetBuy ➝ Buy$60.00 ➝ $86.00Low
12/28/2023Raymond JamesBoost TargetOutperform ➝ Outperform$63.00 ➝ $92.00Low
12/27/2023Needham & Company LLCBoost TargetBuy ➝ Buy$60.00 ➝ $108.00Low
12/27/2023HC WainwrightBoost TargetBuy ➝ Buy$58.00 ➝ $94.00Low
11/9/2023The Goldman Sachs GroupInitiated CoverageBuy$50.00Low
11/7/2023B. RileyInitiated CoverageBuy$66.00Low
11/1/2023HC WainwrightReiterated RatingBuy ➝ Buy$58.00Low
10/20/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$60.00Low
10/20/2023HC WainwrightBoost TargetBuy ➝ Buy$49.00 ➝ $58.00Low
10/9/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$71.00Low
10/9/2023Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$59.00 ➝ $65.00Low
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$59.00Low
8/15/2023Leerink PartnrsReiterated RatingOutperformLow
8/15/2023SVB LeerinkInitiated CoverageOutperform$58.00Low
8/15/2023SVB SecuritiesInitiated CoverageOutperform$58.00Low
8/4/2023Morgan StanleyReiterated RatingOverweight ➝ Overweight$60.00Low
8/4/2023Needham & Company LLCReiterated RatingBuy$60.00Low
8/4/2023HC WainwrightReiterated RatingBuy ➝ Buy$49.00Low
6/22/2023JPMorgan Chase & Co.Boost Target$52.00 ➝ $54.00Low
5/5/2023UBS GroupBoost Target$61.00 ➝ $62.00Low
4/3/2023UBS GroupLower TargetBuy$67.00 ➝ $61.00Low
4/3/2023Cantor FitzgeraldLower TargetOverweight$61.00 ➝ $59.00Low
4/2/2023Bank of AmericaLower Target$50.00 ➝ $42.00Low
3/31/2023HC WainwrightLower TargetBuy$56.00 ➝ $49.00Low
3/7/2023Cantor FitzgeraldReiterated RatingOverweight$61.00N/A
3/6/2023MizuhoInitiated CoverageBuy$80.00Low
3/2/2023The Goldman Sachs GroupLower TargetBuy$56.00 ➝ $48.00Low
3/2/2023JMP SecuritiesReiterated RatingBuy$71.00Low
3/1/2023Needham & Company LLCReiterated RatingBuy$58.00Low
3/1/2023OppenheimerLower TargetOutperform$55.00 ➝ $54.00Low
2/17/2023Bank of AmericaInitiated CoverageNeutral$49.00Low
1/17/2023The Goldman Sachs GroupBoost TargetBuy$47.00 ➝ $56.00Low
12/23/2022Needham & Company LLCLower TargetBuy$60.00 ➝ $58.00Low
12/20/2022Truist FinancialInitiated CoverageBuy$60.00Low
12/16/2022MizuhoInitiated CoverageBuy$80.00Low
12/15/2022UBS GroupLower TargetNeutral$80.00 ➝ $66.00Low
12/15/2022The Goldman Sachs GroupLower TargetBuy$55.00 ➝ $47.00Low
12/15/2022HC WainwrightBoost TargetBuy$29.00 ➝ $56.00Low
12/14/2022OppenheimerLower Target$55.00Low
12/14/2022HC WainwrightLower Target$75.00 ➝ $29.00Low
12/14/2022JMP SecuritiesLower TargetMarket Outperform$82.00 ➝ $71.00Low
12/9/2022JPMorgan Chase & Co.Lower Target$64.00 ➝ $55.00Low
12/8/2022HC WainwrightReiterated RatingBuy$75.00Low
10/11/2022UBS GroupInitiated CoverageBuy$80.00Low
10/3/2022JMP SecuritiesBoost TargetMarket Outperform$53.00 ➝ $82.00Low
9/2/2022MizuhoInitiated CoverageBuy$80.00Low
8/15/2022Cantor FitzgeraldBoost Target$56.00 ➝ $69.00Low
8/12/2022Morgan StanleyBoost Target$11.00 ➝ $15.00Low
8/5/2022Raymond JamesBoost Target$54.00 ➝ $63.00Low
7/15/2022Morgan StanleyBoost TargetOverweight$46.00 ➝ $60.00Low
6/9/2022Piper SandlerBoost TargetOverweight$50.00 ➝ $72.00Medium
5/24/2022HC WainwrightReiterated RatingBuy$75.00Medium
5/24/2022The Goldman Sachs GroupLower TargetBuy$71.00 ➝ $57.00Low
5/16/2022MizuhoBoost TargetBuy ➝ Buy$54.00 ➝ $80.00Medium
5/5/2022Needham & Company LLCBoost Target$52.00 ➝ $60.00High
4/29/2022HC WainwrightBoost Target$69.00 ➝ $75.00High
2/17/2022Cantor FitzgeraldLower Target$57.00 ➝ $53.00High
1/28/2022The Goldman Sachs GroupInitiated CoverageBuy$74.00High
12/21/2021OppenheimerInitiated CoverageOutperform$55.00High
12/21/2021HC WainwrightBoost TargetBuy$62.00 ➝ $69.00High
12/10/2021JPMorgan Chase & Co.Initiated CoverageOverweight$58.00Medium
12/1/2021MizuhoBoost TargetBuy$45.00 ➝ $54.00High
11/4/2021HC WainwrightBoost TargetPositive ➝ Buy$58.00 ➝ $62.00High
11/4/2021JMP SecuritiesReiterated RatingBuyHigh
10/12/2021Cantor FitzgeraldBoost TargetOverweight$48.00 ➝ $57.00Low
10/8/2021HC WainwrightReiterated RatingBuy$58.00Medium
10/8/2021Morgan StanleyBoost TargetOverweight$38.00 ➝ $45.00Medium
10/6/2021Jefferies Financial GroupInitiated CoverageBuy$75.00High
9/7/2021BarclaysBoost TargetOverweight$40.00 ➝ $45.00High
8/9/2021Piper SandlerLower TargetOverweight$42.00 ➝ $40.00Low
8/6/2021HC WainwrightBoost TargetBuy$53.00 ➝ $58.00High
7/20/2021Cantor FitzgeraldBoost TargetPositive ➝ Overweight$35.00 ➝ $48.00High
7/20/2021BarclaysBoost TargetOverweight$28.00 ➝ $40.00High
7/19/2021JMP SecuritiesBoost TargetOutperform ➝ Outperform$26.00 ➝ $44.00High
7/19/2021Raymond JamesBoost TargetOutperform$37.00 ➝ $54.00High
7/19/2021Piper SandlerBoost TargetPositive ➝ Overweight$25.00 ➝ $42.00High
7/19/2021HC WainwrightBoost TargetBuy$41.00 ➝ $53.00High
7/19/2021Needham & Company LLCBoost TargetBuy$33.00 ➝ $48.00High
7/1/2021MizuhoInitiated CoverageBuy$36.00Low
5/11/2021MizuhoBoost TargetBuy$26.00 ➝ $36.00Medium
4/19/2021Morgan StanleyBoost TargetOverweight$24.00 ➝ $35.00Low
3/11/2021Wolfe ResearchInitiated CoverageOutperform$50.00High
2/18/2021BarclaysInitiated CoverageOverweight$28.00High
1/20/2021HC WainwrightBoost TargetBuy$22.00 ➝ $41.00High
12/16/2020Morgan StanleyBoost TargetOverweight$22.00 ➝ $24.00Low
12/14/2020MizuhoLower TargetBuy$31.00 ➝ $26.00High
11/24/2020Raymond JamesReiterated RatingBuyHigh
11/23/2020HC WainwrightLower TargetBuy$43.00 ➝ $22.00High
11/16/2020Needham & Company LLCReiterated RatingBuy$33.00Medium
11/16/2020Morgan StanleyLower TargetOverweight$24.00 ➝ $22.00High
10/28/2020The Goldman Sachs GroupInitiated CoverageNeutral$16.00Low
10/12/2020Morgan StanleyLower TargetOverweight$35.00 ➝ $24.00Low
10/8/2020HC WainwrightLower TargetPositive ➝ Buy$59.00 ➝ $43.00High
10/6/2020Cantor FitzgeraldBoost TargetOverweight$41.00 ➝ $48.00Medium
7/23/2020Piper SandlerBoost TargetOverweight$33.00 ➝ $36.00Low
7/23/2020HC WainwrightBoost TargetBuy$38.00 ➝ $59.00Low
7/15/2020Cantor FitzgeraldBoost TargetOverweight$29.00 ➝ $41.00High
7/15/2020JMP SecuritiesBoost TargetOutperform$23.00 ➝ $29.00High
7/14/2020Needham & Company LLCBoost TargetBuy$34.00 ➝ $45.00High
7/14/2020Piper SandlerBoost Target$28.00 ➝ $33.00High
7/14/2020HC WainwrightBoost TargetBuy$35.00 ➝ $38.00High
7/10/2020Raymond JamesInitiated CoverageStrong-Buy$39.00High
7/7/2020Morgan StanleyBoost TargetOverweight$29.00 ➝ $35.00High
5/23/2020MizuhoInitiated CoverageBuy$31.00Low
5/12/2020Morgan StanleyBoost TargetOverweight$25.00 ➝ $29.00Low
5/11/2020HC WainwrightBoost TargetPositive ➝ Buy$30.00 ➝ $35.00High
5/7/2020Needham & Company LLCReiterated RatingBuy$24.00Low
5/4/2020MizuhoInitiated CoverageBuy$31.00High
4/27/2020Morgan StanleyReiterated RatingBuy$25.00Low
4/24/2020HC WainwrightReiterated RatingBuyMedium
4/19/2020Morgan StanleyUpgradeEqual Weight ➝ OverweightLow
4/17/2020Cantor FitzgeraldBoost TargetOverweight$12.00 ➝ $23.00High
4/14/2020HC WainwrightReiterated RatingBuy$30.00Medium
4/14/2020Needham & Company LLCReiterated RatingBuy$24.00Low
4/9/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$14.00 ➝ $25.00High
3/31/2020HC WainwrightReiterated RatingBuy$30.00High
3/4/2020Needham & Company LLCReiterated RatingBuy$24.00Medium
2/26/2020HC WainwrightReiterated RatingBuy$30.00Low
2/7/2020HC WainwrightReiterated RatingBuyHigh
11/1/2019Needham & Company LLCReiterated RatingBuy$24.00High
10/4/2019Needham & Company LLCReiterated RatingBuy$16.00Low
10/4/2019HC WainwrightReiterated RatingBuy$26.00Medium
9/16/2019Piper Sandler CompaniesReiterated RatingOverweight$14.00 ➝ $20.00High
9/13/2019JMP SecuritiesSet TargetBuy$23.00Medium
9/6/2019Cantor FitzgeraldReiterated RatingOverweight$14.00 ➝ $20.00Medium
8/9/2019Needham & Company LLCSet TargetBuy$16.00Medium
8/9/2019Morgan StanleySet TargetHold$16.00Medium
7/15/2019Morgan StanleySet TargetHold$11.00High
7/15/2019Piper Sandler CompaniesSet TargetBuy$14.00High
5/10/2019Cantor FitzgeraldReiterated RatingBuy$14.00Medium
5/6/2019HC WainwrightBoost TargetBuy$21.00 ➝ $26.00Medium
4/23/2019HC WainwrightSet TargetBuy$21.00High
(Data available from 4/16/2019 forward)

News Sentiment Rating

0.73 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 11 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/19/2023
  • 4 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
10/19/2023
  • 2 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/18/2023
  • 4 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
12/18/2023
  • 20 very positive mentions
  • 46 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
1/17/2024
  • 13 very positive mentions
  • 25 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
2/16/2024
  • 20 very positive mentions
  • 47 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
3/17/2024
  • 15 very positive mentions
  • 19 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
4/16/2024

Current Sentiment

  • 15 very positive mentions
  • 19 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Cytokinetics logo
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $69.06
Low: $66.55
High: $69.66

50 Day Range

MA: $71.93
Low: $63.75
High: $80.99

52 Week Range

Now: $69.06
Low: $25.98
High: $110.25

Volume

160,729 shs

Average Volume

3,081,652 shs

Market Capitalization

$7.22 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.68

Frequently Asked Questions

What sell-side analysts currently cover shares of Cytokinetics?

The following equities research analysts have issued research reports on Cytokinetics in the last twelve months: B. Riley, Cantor Fitzgerald, HC Wainwright, JMP Securities, JPMorgan Chase & Co., Leerink Partnrs, Mizuho, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Raymond James, StockNews.com, SVB Leerink LLC, SVB Securities, The Goldman Sachs Group, Inc., Truist Financial Co., and UBS Group AG.
View the latest analyst ratings for CYTK.

What is the current price target for Cytokinetics?

15 Wall Street analysts have set twelve-month price targets for Cytokinetics in the last year. Their average twelve-month price target is $79.33, suggesting a possible upside of 14.9%. Needham & Company LLC has the highest price target set, predicting CYTK will reach $108.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $50.00 for Cytokinetics in the next year.
View the latest price targets for CYTK.

What is the current consensus analyst rating for Cytokinetics?

Cytokinetics currently has 2 hold ratings and 13 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for CYTK.

What other companies compete with Cytokinetics?

How do I contact Cytokinetics' investor relations team?

Cytokinetics' physical mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company's listed phone number is (650) 624-3000 and its investor relations email address is [email protected]. The official website for Cytokinetics is www.cytokinetics.com. Learn More about contacing Cytokinetics investor relations.